QIAGEN to Present at the JPMorgan 26th Annual Healthcare Conference
Dec 12 2007

QIAGEN to Present at the JPMorgan 26th Annual Healthcare Conference

Venlo, The Netherlands, December 12, 2007 - QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that it will present at the JPMorgan 26th Annual Healthcare Conference at 10:30 a.m. PT on Tuesday, January 8, 2008. The conference is being held at Westin St. Francis in San Francisco, California.

Peer M. Schatz, QIAGEN's Chief Executive Officer will provide an overview of the company, discuss QIAGEN's business as well as recent developments and outline future opportunities. QIAGEN's presentation will be webcasted live for investors and available for replay for a period of three months following the conference. The presentation can be accessed in the Investor Relations section at the Company's web site at http://www.qiagen.com.

About QIAGEN:

QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 2,600 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. Further information about QIAGEN can be found at www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, women's health/HPV testing markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, changing relationships with customers, suppliers and strategic partners, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Contacts


IR QIAGEN N.V.

phone +49 2103 29 11710

fax +49 2103 29 21710

email ir@qiagen.com

FOLLOW US ON SOCIAL MEDIA

Share this page